A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 25
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : SSc-PAH
Long Form : systemic sclerosis-associated pulmonary arterial hypertension
No. Year Title Co-occurring Abbreviation
2020 Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. PAH, SSc
2020 Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody. SSc
2019 Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment. SSc
2019 Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH). IPAH, PA, PAH, SSc
2018 Non-invasive right ventricular load adaptability indices in patients with scleroderma-associated pulmonary arterial hypertension. IPAH
2018 Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. AUC, FSTL3
2018 The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. CMRI, LV, pGLS, pGLSRe, PLS, pLSRa, pLSRs, RV, RVFW, SR, SRs
2017 Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. IPAH, RV
2017 Dynamics of the human antibody repertoire after B cell depletion in systemic sclerosis. IgH
10  2016 Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). IPAH, PAH, SSc
11  2016 Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study. RR
12  2016 The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. ADMA
13  2015 Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. IQR, RV
14  2012 Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients. IPAH, PBMCs, SSc, SSc-PH-ILD
15  2012 Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. IPAH
16  2012 N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. NT-proBNP, PAP, RHC, SSc, TTE
17  2012 Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. CrI, HR, IPAH, PS
18  2011 CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. CTPA, mPAP, NPV
19  2011 Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. IPAH, PAH
20  2011 Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. DLCO, GDF, IPAH, PAH, SSc
21  2010 Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. 6MWD, NYHA
22  2010 Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. FC, NYHA
23  2009 Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. SLE-PAH
24  2008 Prognostic factors for survival in scleroderma associated pulmonary arterial hypertension. KM, mRAP, sPAP
25  2006 Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. ---